Rybelsus (Oral Semaglutide 14 mg, Diabetes)

Rybelsus is Novo Nordisk's once-daily oral semaglutide tablet approved in September 2019 for glycemic control in adults with type 2 diabetes. It was the world's first oral GLP-1 receptor agonist — a significant pharmaceutical achievement, given that GLP-1 peptides are ordinarily destroyed by gastric acid and proteases when taken by mouth. Rybelsus uses the proprietary SNAC (sodium N-[8-(2-hydroxybenzoyl)aminocaprylate]) absorption enhancer technology, which transiently raises local gastric pH and facilitates semaglutide absorption across the gastric mucosa. The mechanism requires strict fasting conditions: Rybelsus must be taken on an empty stomach with no more than 120 mL of plain water, with no food, drink, or other medications for at least 30 minutes afterward. Available in 3 mg, 7 mg, and 14 mg doses, Rybelsus produces meaningful glycemic control and modest weight loss at the 14 mg dose — approximately 4-5 kg in the PIONEER trials — making it inferior to injectable semaglutide for weight management purposes. However, in October 2025, the FDA approved Rybelsus for an expanded indication: cardiovascular risk reduction in adults with type 2 diabetes and established or high cardiovascular risk, based on the SOUL trial (n=9,650), which demonstrated a 14% relative reduction in major adverse cardiovascular events versus placebo over 4 years. This added the critical CV indication that transforms Rybelsus from a glycemic drug into a comprehensive metabolic risk-reduction tool for T2D patients who prefer oral therapy. Rybelsus occupies an important niche: it is the only oral GLP-1 approved for both glycemic control and cardiovascular risk reduction in type 2 diabetes. Monthly list price is approximately $900-$1,000 without insurance, though diabetes coverage in commercial and Medicare plans is generally more robust than for weight-loss-specific GLP-1s. The arrival of oral Wegovy (25 mg) and Foundayo has made Rybelsus less prominent in the weight-loss conversation, but it remains the definitive oral GLP-1 for T2D with established CV disease.